Adult Dosing

Vernal keratoconjunctivitis

• 1-2 drops in the affected eye(s) qid, up to 3 months

Vernal conjunctivitis

• 1-2 drops in the affected eye(s) qid, up to 3 months

Vernal keratitis

• 1-2 drops in the affected eye(s) qid, up to 3 months

Note:

• For ophthalmic use only

Pediatric Dosing

Vernal keratoconjunctivitis

• <2 yrs: Safety and effectiveness have not been established
• >2 yrs: 1-2 drops in the affected eye(s) qid, up to 3 months

Vernal conjunctivitis

• <2 yrs: Safety and effectiveness have not been established
• >2 yrs: 1-2 drops in the affected eye(s) qid, up to 3 months

Vernal keratitis

• <2 yrs: Safety and effectiveness have not been established
• >2 yrs: 1-2 drops in the affected eye(s) qid, up to 3 months

Note:

• For ophthalmic use only

[Outline]

• Adult Dosing
• Pediatric Dosing

• Treatment of vernal keratoconjunctivitis, vernal conjunctivitis, and vernal keratitis

• Hypersensitivity to any of the ingredients of the product

• N/A

Renal Dose Adjustment

• Renal impairment: Dose adjustments not defined

Hepatic Dose Adjustment

• Hepatic impairment: Dose adjustments not defined

• Lodoxamide is intended for topical ophthalmic use only; not recommended by any other route
• Patients should avoid touching the tip of the dropper to any surface in order to prevent contamination
• Soft contact lenses should not be worn during lodoxamide therapy
• Transient burning or stinging following instillation of the eye drops has been reported in a few patients. If these symptoms persist, the patient should contact the prescribing physician

Pregnancy Category:B

Breastfeeding: No published information exists regarding lodoxamide use during lactation. However, levels in breast milk are likely to be low with the use of eye drops. To reduce the amount of drug that reaches the breast milk after using eye drops, place pressure over the tear duct by the corner of the eye for about 1 min and remove the excess with an absorbent tissue. This information is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 16 May 2011). As many drugs are excreted in human milk, manufacturer advises caution.

• CNS: Headache
• EENT: Corneal ulcer, ocular edema, corneal abrasion; transient ocular burning, ocular stinging, or discomfort upon instillation; ocular pruritus, blurred vision, dry eye, tearing/discharge, hyperemia, crystalline deposits, foreign body sensation

• Mast cell stabilizer; inhibits Type I immediate hypersensitivity reaction; inhibits the increases in cutaneous vascular permeability associated with reagin or IgE and antigen-mediated reactions
• Metabolism: Unknown
• Excretion: Unknown
• Half-life: Unknown

US Trade Name(s)

• Alomide

US Availability

Alomide

• OPTH SOLN: 0.1%

Canadian Trade Name(s)

• Alomide

Canadian Availability

Alomide

• OPTH SOLN: 0.1%

UK Trade Name(s)

• Alomide

UK Availability

Alomide

• OPTH SOLN: 0.1%

Australian Trade Name(s)

• Lomide

Australian Availability

Lomide

• OPTH SOLN: 0.1%

[Outline]

Ophthalmic

Mast Cell Stabilizers

Allergy & Immunology

Mast Cell Stabilizers

Pricing data from www.DrugStore.com in U.S.A.

• Alomide 0.1 % SOLN [Bottle] (ALCON VISION)
  10 % = $114.41
  30 % = $333.43

Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.